SUNNYVALE, Calif., Oct. 9, 2018 /PRNewswire/ -- Accuray Incorporated
(NASDAQ: ARAY) announced today that the Klinikum rechts der Isar
der Technischen Universität München (TUM) clinical team has treated
the first cancer patients in Germany with the innovative
Radixact® System. This next-generation helical radiation
therapy technology replaced an existing, earlier generation
TomoTherapy® System at TUM, reinforcing its value to the
hospital as a workhorse radiation therapy device capable of
treating a wide range of indications from simple to complex. The
TUM patients were treated for breast cancer, head and neck tumors,
prostate cancer and spinal tumors.
The TUM hospital is focused on providing patients with
personalized care using state-of-the-art technology that can
deliver high-precision radiation therapy with minimal side effects.
The specialized team of experts in radiation therapy and medical
physics, and specially trained medical-technical radiology
assistants, work closely with other disciplines within the
university hospital, referring physicians, and other institutions,
to ensure patients receive the best possible treatment for their
specific type of cancer.
"Our radiotherapy team has been using the TomoTherapy platform
for more than 10 years and have found it to be an essential
component of cancer care at the hospital. When it came time to
purchase a new radiation therapy device, our long-term positive
experiences made the decision to upgrade to the Radixact System an
easy one," said Univ. Prof. Dr. med. Stephanie E. Combs, Chair of the Department of
Radiation Oncology at Klinikum rechts der Isar Technische
Universität München. "We treat patients with a wide variety of
tumor types and are excited about the opportunity to treat even
complex cases much more quickly, without sacrificing precision or
accuracy. In the future, we look forward to improved image
guidance, and motion tracking and compensation, enhancements that
we believe will enable us to significantly improve patient
care."
State-of-the-art technology is designed to empower clinicians
to improve their patients' care
- The system is fully-integrated with the Accuray
Precision® Treatment Planning System and the iDMS™ Data
Management System, enabling the clinical team to increase the ease
and speed with which they create treatment plans and deliver
precise radiation treatments
- The Radixact System delivers the same highly conformal and
homogeneous dose distribution faster than the previous TomoTherapy
platform, with a higher dose rate (1000 MU/minute) and imaging time
that is 66 percent faster. A combination of higher dose output and
faster image acquisition can shorten treatment times, while
improving the patient experience
- A fully-integrated, automated adaptive solution, PreciseART™
Adaptive Radiation Therapy Software, makes adaptive radiotherapy
simple and practical. The software enables physicians to easily
decide when adaptation of radiation delivery during the course of
treatment would be beneficial due to changes in tumor size and
patient anatomy
- The CTrue™ IR (Iterative Reconstruction) image guidance
software improves soft-tissue contrast and reduces noise, enhancing
image quality, while maintaining the same low imaging dose and fast
reconstruction time as earlier versions of the software. Patient
workflows are also more efficient, facilitating the delivery of
precise treatments more quickly, for more patients
"We are proud to partner with Professor Combs and her team as
they expand access to the Radixact System to German patients," said
Lionel Hadjadjeba, M.D., Senior Vice President, and Chief
Commercial Officer at Accuray. "Our hope is that our advanced and
differentiated approach to treating cancer will provide a new
option for patients requiring radiation treatments."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, and patient experiences and outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, the company's ability to develop
new products or enhance existing products to meet customers' needs,
the company's ability to maintain or increase its gross margins on
product sales and services, the company's ability to meet the
covenants under its credit facilities, the company's ability to
convert backlog to revenue, risks and uncertainties related to the
China Class A license announcement and such other risks identified
under the heading "Risk Factors" in the company's annual report on
Form 10-K, filed with the Securities and Exchange Commission (the
"SEC") on August 24, 2018 and as
updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth
Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6662
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/technische-universitat-munchen-hospital-is-first-in-germany-to-treat-cancer-patients-with-accuray-radixact-system-300727301.html
SOURCE Accuray Incorporated